CapsoVision, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $345.9M
- Price
- $6.50
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.29%
- Volume
- 69.5K
About
CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon). It also provides CapsoCloud cloud-based software-as-a-service ecosystem as an off-premises video access and download solution; CapsoView, a data access reading device for viewing capsule videos; CapsoAccess, a Capsule data access system; and CapsoRetrieve, a retrieval kit to recover the capsule using a magnetic wand, as well as capsule video reading services. The company serves gastrointestinal medical practices, clinics, and hospitals. It sells its products to distributor customers who resell products. The company was formerly known as Capso Vision Inc. and changed its name to CapsoVision, Inc. in May 2016. CapsoVision, Inc. was incorporated in 2005 and is headquartered in Saratoga, California.
Quick stats
Shares outstanding53.2M
Computed float34.1M
Float / shares64.1%
Cash runway (months)0.5
Key info
SectorHealthcare
IndustryMedical - Devices
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001378325
Websitehttps://capsovision.com
AI Summary
AI-generated1/21
standardbullishfda approval
CapsoVision Announces FDA Clearance of AI Highlights for CapsoCam Plus®
CapsoVision received FDA clearance for AI Highlights, an AI-assisted reading tool for its CapsoCam Plus capsule endoscopy system, cleared September 25, 2026.
The tool flags suspected abnormal lesions to reduce physician review time and integrates with CapsoView and CapsoCloud workflows; it follows an earlier international launch including the EU under MDR.
The clearance supports physician efficiency and capsule endoscopy adoption, though the tool supplements rather than replaces diagnostic interpretation.